This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): Garenoxacin, BMS-284756, T3811ME, T-3811
Description: Geninax is a novel quinolone antibacterial agent that has shown potent activity against a wide range of Gram-positive and Gram-negative bacterial pathogens, including anaerobic organisms, and resistant strains such as penicillin-resistant Streptococcus pneumoniae. Garenoxacin is more active than marketed quinolones against common Gram-positive bacteria, as well as some strains that are resistant to ciprofloxacin.
Geninax and Bristol Myers Squibb
Geninax was originally developed by Toyama Chemical. They licensed the compound to Bristol Myers Squibb in 1998. This license was terminated in September 2003.
Toyoma and Geninax
On May 22, 2004, Toyama Chemical entered into a definitive license agreement for Geninax with Schering-Plough Corporation. Under the terms of the agreement, Toyama has granted to Schering-Plough exclusive rights to develop, use and sell Geninax worldwide, excluding Japan, Korea and China.
Toyoma and Astellas
In March 2006, Toyoma and Astellas concluded a basic licensing agreement for the marketing and joint development in Japan of oral formulations of Geninax. Toyoma will manufacture the products and supply them to Astellas through Taisho Toyama Pharmaceutical. Taisho Toyama and Astellas will co-promote the products under the same brand name. Sales and distribution will be handled by Astellas. Toyama will receive an upfront...See full deal structure in Biomedtracker
Partners: Toyama Chemical Co., Ltd. Astellas Pharma, Inc. Shenzhen Main Luck Pharmaceuticals Inc.
Pink Sheet Geninax AC review
Pink Sheet Advisory committee cancellations
Additional information available to subscribers only: